americanpharmaceuticalreviewJanuary 06, 2021
Tag: grunenthal , Nociceptin , orphanin , neuropathic pain
Grünenthal announced the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain.
The Phase I trial will include 76 healthy participants. The trial aims to demonstrate a favorable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound following single and multiple-ascending doses. The results of the study are expected to be available in 2021.
"Pain remains a high unmet medical need that we strive to address with innovative medicines. Progressing our peripheral NOP agonist into clinical development is a major success in our efforts to build an industry-leading pipeline of investigational medicines," said Jan Adams, M.D., Chief Scientific Officer, Grünenthal. "By driving the development of innovative medicines, we strive to change the life of patients for the better and make progress towards our vision of a world free of pain."
The investigational medicine is a Grünenthal proprietary development based on extensive research in the field of the NOP receptor and currently the most advanced compound of the company's peripheral, selective Nociceptin/orphanin FQ (N/OFQ) peptide receptor agonist program. Pre-clinical data has shown an analgesic effect in a wide range of models. In addition, the investigational medicine's selectivity for the NOP receptor, combined with its peripherally restricted mode of action, may lead to an improved safety profile compared to the currently available standards of care.
Neuropathic pain is defined as pain that arises as a direct consequence of a lesion or diseases affecting the somatosensory system, i.e. a complex system of sensory neurons and pathways that responds to changes at the surface or inside the body. Neuropathic pain can result from nerve injury or disease affecting the peripheral or central nervous system. It is characterized by symptoms such as shooting or burning pain, numbness, altered sensation, and sensations that are very difficult to describe. General population studies, using validated screening instruments, have found that 7-10% of adults currently have chronic pain with neuropathic characteristics. According to the International Association for the Study of Pain (IASP), this pain is generally more severe, and is associated with worse health, in every measured dimension compared to non-neuropathic pain. 17% percent of those who had pain with neuropathic characteristics had health-related quality of life scores equivalent to "worse than death" in a U.K study, compared to only 3% of those without neuropathic characteristics. Patients with neuropathic pain generally do not respond to analgesics such as acetaminophen, NSAIDs or weak opioids such as codeine. Despite the availability of various treatment options as well as guidelines, treatment remains a challenge.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: